Success Metrics

Clinical Success Rate
88.9%

Based on 8 completed trials

Completion Rate
89%(8/9)
Active Trials
0(0%)
Results Posted
13%(1 trials)
Terminated
1(8%)

Phase Distribution

Ph not_applicable
1
8%
Ph phase_2
6
50%
Ph phase_1
1
8%
Ph phase_4
3
25%
Ph phase_3
1
8%

Phase Distribution

1

Early Stage

6

Mid Stage

4

Late Stage

Phase Distribution12 total trials
Phase 1Safety & dosage
1(8.3%)
Phase 2Efficacy & side effects
6(50.0%)
Phase 3Large-scale testing
1(8.3%)
Phase 4Post-market surveillance
3(25.0%)
N/ANon-phased studies
1(8.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

88.9%

8 of 9 finished

Non-Completion Rate

11.1%

1 ended early

Currently Active

0

trials recruiting

Total Trials

12

all time

Status Distribution
Completed(8)
Terminated(1)
Other(3)

Detailed Status

Completed8
unknown3
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
0
Success Rate
88.9%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (8.3%)
Phase 26 (50.0%)
Phase 31 (8.3%)
Phase 43 (25.0%)
N/A1 (8.3%)

Trials by Status

terminated18%
unknown325%
completed867%

Recent Activity

0 active trials
Showing 5 of 12
completedphase_1

Open Label Phase I Study To Evaluate the Safety of Combination Therapy With AZT and Interferon-Beta in Patients With AIDS Related Kaposi's Sarcoma

NCT00000695
unknownphase_2

IFN-beta 1b and Remdesivir for COVID19

NCT04647695
completedphase_4

Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current Therapy

NCT03177083
unknownphase_2

IFN Beta-1b and Ribavirin for Covid-19

NCT04494399
completedphase_2

Double Therapy With IFN-beta 1b and Hydroxychloroquine

NCT04350281
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT00000695Phase 1

Open Label Phase I Study To Evaluate the Safety of Combination Therapy With AZT and Interferon-Beta in Patients With AIDS Related Kaposi's Sarcoma

Completed
NCT04647695Phase 2

IFN-beta 1b and Remdesivir for COVID19

Unknown
NCT03177083Phase 4

Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current Therapy

Completed
NCT04494399Phase 2

IFN Beta-1b and Ribavirin for Covid-19

Unknown
NCT04350281Phase 2

Double Therapy With IFN-beta 1b and Hydroxychloroquine

Completed
NCT04465695Phase 2

Dual Therapy With Interferon Beta-1b and Clofazimine for COVID-19

Unknown
NCT04343768Phase 2

An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial

Completed
NCT04276688Phase 2

Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment

Completed
NCT01144052Phase 4

Natalizumab De-escalation With Interferon Beta-1b

Completed
NCT01701856Phase 4

Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis

Terminated
NCT00002238Phase 3

Phase III Randomized Double-Blind Placebo Controlled Study To Evaluate the Safety and Efficacy of Betaseron in AIDS and Advanced ARC Patients Receiving a Reduced-Dose AZT Regimen

Completed
NCT00002299Not Applicable

The Safety and Effectiveness of Ganciclovir Plus Interferon Beta in Preventing the Return of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS

Completed

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12